Vor Biopharma 1 article

The core modality behind Vor Biopharma is engineered hematopoietic stem cells; as a genome-edited hematopoietic cell-therapy company, it also relies on CRISPR edited blood stem cells to shape cellular function or delivery. Its cell-therapy architecture extends from hematopoietic stem cell transplantation to acute myeloid leukemia cell therapy, with targeted therapy compatible stem cells shaping potency, persistence, targeting or immune compatibility. GenoMethods keeps the cell-therapy modality and individual cellular products separate; the platform identity of Vor Biopharma also includes ex vivo genome editing.

Clinical Trials & Evidence

September 27, 2026, 5:42 PM · 4 mins read

Gene edited stem cell transplants shield healthy blood from targeted leukemia therapy

A clinical trial shows that deleting CD33 from donor stem cells lets targeted therapies attack leukemia while sparing healthy blood. This marks a major step for aggressive blood cancers.